Literature DB >> 15917553

Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance.

Wehbeh Wehbeh1, Roberto Rojas-Diaz, Xinying Li, Noriel Mariano, Louise Grenner, Sorana Segal-Maurer, Barbara Tommasulo, Karl Drlica, Carl Urban, James J Rahal.   

Abstract

Quinolone-resistant Streptococcus agalactiae bacteria were recovered from single-patient isolates and found to contain mutations in the gyrase and topoisomerase IV genes. Pulsed-field gel electrophoresis demonstrated that four isolates from the same long-term care facility were closely related; in seven cases, quinolone-resistant Haemophilus influenzae and S. agalactiae bacteria were isolated from the same patient.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15917553      PMCID： PMC1140524          DOI： 10.1128/AAC.49.6.2495-2497.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study--1996. Sentinel Health Unit Surveillance System Site Coordinators.

Authors:  G J Tyrrell; L D Senzilet; J S Spika; D A Kertesz; M Alagaratnam; M Lovgren; J A Talbot
Journal:  J Infect Dis       Date:  2000-06-29       Impact factor: 5.226

2.  Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci.

Authors:  Daniel J Diekema; Janet I Andrews; Holly Huynh; Paul R Rhomberg; Stella R Doktor; Jill Beyer; Virginia D Shortridge; Robert K Flamm; Ronald N Jones; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

3.  Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol Team.

Authors:  D C Perlman; W M El Sadr; L B Heifets; E T Nelson; J P Matts; K Chirgwin; N Salomon; E E Telzak; O Klein; B N Kreiswirth; J M Musser; R Hafner
Journal:  AIDS       Date:  1997-10       Impact factor: 4.177

Review 4.  Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature, 1962-1998.

Authors:  A Sambola; J M Miro; M P Tornos; B Almirante; A Moreno-Torrico; M Gurgui; E Martinez; A Del Rio; M Azqueta; F Marco; J M Gatell
Journal:  Clin Infect Dis       Date:  2002-05-24       Impact factor: 9.079

5.  Group B streptococcal disease in nonpregnant adults.

Authors:  M M Farley
Journal:  Clin Infect Dis       Date:  2001-07-20       Impact factor: 9.079

6.  Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective.

Authors:  D R Murdoch; L B Reller
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

7.  Resistance of group B streptococcus to selected antibiotics, including erythromycin and clindamycin.

Authors:  Judith S Heelan; Meredith E Hasenbein; Alexander J McAdam
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

8.  First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC.

Authors:  Yoshiaki Kawamura; Hiromitsu Fujiwara; Noriko Mishima; Yuko Tanaka; Ayako Tanimoto; Shiro Ikawa; Youko Itoh; Takayuki Ezaki
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  "Collateral damage" from cephalosporin or quinolone antibiotic therapy.

Authors:  David L Paterson
Journal:  Clin Infect Dis       Date:  2004-05-15       Impact factor: 9.079

10.  Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology.

Authors:  Jawad Nazir; Carl Urban; Noriel Mariano; Janice Burns; Barbara Tommasulo; Carl Rosenberg; Sorana Segal-Maurer; James J Rahal
Journal:  Clin Infect Dis       Date:  2004-05-12       Impact factor: 9.079
View more
  17 in total

1.  Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.

Authors:  Noriyuki Nagano; Yukiko Nagano; Kouji Kimura; Kiyoko Tamai; Hideji Yanagisawa; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

2.  Emergence of the first levofloxacin-resistant strains of Streptococcus agalactiae isolated in Italy.

Authors:  G Piccinelli; F Gargiulo; S Corbellini; G Ravizzola; C Bonfanti; A Caruso; M A De Francesco
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

3.  Changing Epidemiology of Group B Streptococcus Susceptibility to Fluoroquinolones and Aminoglycosides in France.

Authors:  Constantin Hays; Mathilde Louis; Céline Plainvert; Nicolas Dmytruk; Gérald Touak; Patrick Trieu-Cuot; Claire Poyart; Asmaa Tazi
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

4.  High prevalence of fluoroquinolone-resistant group B streptococci among clinical isolates in China and predominance of sequence type 19 with serotype III.

Authors:  Hui Wang; Chunjiang Zhao; Wenqiang He; Feifei Zhang; Liyan Zhang; Bin Cao; Ziyong Sun; Yingchun Xu; Qing Yang; Yaning Mei; Bijie Hu; Yunzhuo Chu; Kang Liao; Yunsong Yu; Zhidong Hu; Yuxing Ni
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

5.  Emerging fluoroquinolone resistance in Streptococcus agalactiae in South Korea.

Authors:  M Ki; U Srinivasan; K Y Oh; M Y Kim; J-H Shin; H L Hong; T Dang; Z Britt; B Foxman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-04       Impact factor: 3.267

6.  Molecular characterization of adult-colonizing Streptococcus agalactiae from an area-based surveillance study in Romania.

Authors:  C-R Usein; L Grigore; R Georgescu; V Cristea; M Bãltoiu; M Strãuţ
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-23       Impact factor: 3.267

7.  Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.

Authors:  Hsiu-Mei Wu; Rajendra Prasad Janapatla; Yueh-Ren Ho; Kuei-Hsiang Hung; Chi-Wen Wu; Jing-Jou Yan; Jiunn-Jong Wu
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

8.  Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.

Authors:  Nadezhda German; Muhammad Malik; Jonathan D Rosen; Karl Drlica; Robert J Kerns
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

9.  Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.

Authors:  Somay Yamagata Murayama; Chizuko Seki; Hiroshi Sakata; Katsuhiko Sunaoshi; Eiichi Nakayama; Satoshi Iwata; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

10.  Fluoroquinolone-resistant group B streptococci in acute exacerbation of chronic bronchitis.

Authors:  Asmaa Tazi; Thomas Gueudet; Emanuelle Varon; Liliane Gilly; Patrick Trieu-Cuot; Claire Poyart
Journal:  Emerg Infect Dis       Date:  2008-02       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.